ACEI/ARBs increase ACE2 receptor expression; SARS-CoV-2 might utilise this increase to result in severe disease |
A |
[6] |
Severely ill male patients with heart injury, hyperglycemia, and high-dose corticosteroid use may have a higher risk of death |
B |
[7] |
The use of ACEI and/or ARBs can increase the risk of severity of COVID-19 |
A |
[8] |
Comorbidities such as COPD, diabetes, hypertension, and malignancy predispose individuals with COVID-19 to adverse clinical outcomes |
A |
[9] |
Does not support discontinuation of ACEI/ARB medications that are clinically indicated in the context of the COVID-19 pandemic |
B |
[10] |
A significant difference in the use of ACEI/ARB among patients with different severities of the disease |
B |
[11] |
ACEI/ARBs reduce IL-6 and increase CD3 and CD8, thus reducing COVID-19 severity; ACEI and ARBs are beneficial in COVID-19 |
A |
[12] |
AT1R blockers, including ARBs, can help reduce COVID-19 morbidity and mortality |
A |
[13] |
Animal data: increasing ACE2 expression can help protect against pulmonary and cardiovascular hazards; recommend continuing the use of ACEI and ARBs to manage hypertension in COVID-19 patients |
A |
[14] |
RAAS inhibitors were shown to be possibly associated with a lower risk of mortality |
B |
[15] |